EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Mesenchymal stem cell therapy for Crohn's perianal fistula—a real‐world experience

Ian White iD, Henit Yanai, Irit Avni, Moran Slavin, Timna Naftali, Shifra Tovi, Iris Dotan, Nir Wasserberg

Colorectal Disease · 2024

DOI: 10.1111/codi.16830 ↗

At a glance

Journal article in Colorectal Disease, 2024. Written by Ian White and 7 co-authors. Institution: Colorectal Unit, Division of Surgery, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel. Major MEDLINE topics: Crohn Disease, Mesenchymal Stem Cell Transplantation, Rectal Fistula, Mesenchymal Stem Cells. Cited 16 times so far (Crossref); 17 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Aim

Remission rates of medically and surgically treated complex perianal fistulas in Crohn's disease are low. Recently, trials have demonstrated the potential for long‐term remission with local injection of allogeneic adipose‐derived mesenchymal stem cells (darvadstrocel). Our aim was to analyse outcomes from our real‐world experience with this new treatment.

Methods

All patients with Crohn's disease suffering complex perianal fistulas who consecutively underwent administration of darvadstrocel at two centres were followed up and evaluated. Patients were assessed for clinical remission, response, failure, and any complications during follow‐up. The results of all patients with a minimum of 3 months’ follow‐up are presented.

Results

Thirty‐three patients with Crohn's disease and complex perianal fistulas were included. Of these, 20 (61%) experienced clinical remission that was maintained for a mean follow‐up of 14 (3–32) months. A total of 24 of 33 (73%) experienced at least 3 months of clinical remission, with four later having recurrence (3–12 months). Among the remaining nine patients who did not experience clinical remission, two (6%) had partial remission (such as one of two fistulas closing), two (6%) showed signs of response but not remission, and five (15%) showed no signs of healing. The mean time to maintained clinical remission was 6 weeks (range 2 weeks to 6 months), and there were no severe adverse events.

Conclusion

In this real‐world experience, treatment of Crohn's disease complex perianal fistulas with darvadstrocel had a 61% success rate for maintained clinical remission.

Subjects

MeSH terms (MEDLINE)

Crohn DiseaseMesenchymal Stem Cell TransplantationRectal FistulaMesenchymal Stem CellsHumansTreatment OutcomeImmunosuppressive Agents

Author keywords

Crohn's diseasemesenchymal stem cell therapyperianal fistula

Substances

Immunosuppressive Agents

Authors and institutions

  • Colorectal Unit, Division of Surgery, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel.
  • Surgery B Department, Meir Medical Center, Kfar Saba, Israel.
  • Gastroenterology Department, Meir Medical Center, Kfar Saba, Israel.

ORCID profiles: Ian White

Cite

APA

White, I., Yanai, H., Avni, I., Slavin, M., Naftali, T., Tovi, S., Dotan, I., & Wasserberg, N. (2024). Mesenchymal stem cell therapy for Crohn's perianal fistula—a real‐world experience. Colorectal Disease. https://doi.org/10.1111/codi.16830

Vancouver

White I, Yanai H, Avni I, Slavin M, Naftali T, Tovi S, et al. Mesenchymal stem cell therapy for Crohn's perianal fistula—a real‐world experience. Colorectal Disease. 2024. doi:10.1111/codi.16830

BibTeX
@article{White2024,
  author = {White, Ian and Yanai, Henit and Avni, Irit and Slavin, Moran and Naftali, Timna and Tovi, Shifra and Dotan, Iris and Wasserberg, Nir},
  title = {Mesenchymal stem cell therapy for Crohn's perianal fistula—a real‐world experience},
  journal = {Colorectal Disease},
  year = {2024},
  doi = {10.1111/codi.16830}
}
Start for free →